CYTX Cytori Therapeutics Inc.

0.32
+0.01  (+2%)
Previous Close 0.32
Open 0.32
Price To Book 0.68
Market Cap 4250854
Shares 13,201,410
Volume 132,440
Short Ratio
Av. Daily Volume 412,135

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184422
  2. 8-K - Current report 181184286
  3. EFFECT - Notice of Effectiveness 181111931
  4. 424B3 - Prospectus [Rule 424(b)(3)] 181111148
  5. UPLOAD [Cover] - SEC-generated letter

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released June 24, 2017 - endpoints not met.
ECCS-50
Scleroderma
Phase 2 interim data released February 2016 noted that the pre-specified primary endpoint did not obtain statistical significance. Full data due 3Q 2016
ECCO-50 cellular therapeutic
Osteoarthritis of the knee
Phase 2 planned.
ATI-1123
Solid Tumors
Phase 2 data due 4Q 2018.
SCLERADEC II
Scleroderma

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184422
  2. 8-K - Current report 181184286
  3. EFFECT - Notice of Effectiveness 181111931
  4. 424B3 - Prospectus [Rule 424(b)(3)] 181111148
  5. UPLOAD [Cover] - SEC-generated letter
  6. CORRESP [Cover] - Correspondence
  7. S-1 - General form for registration of securities under the Securities Act of 1933 181082230
  8. 8-K - Current report 181081865
  9. 8-K - Current report 181051312
  10. 8-K - Current report 181050604